Completed PHASE3 INTERVENTIONAL NCT00115609

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions HIV Infections Tuberculosis

Interventions efavirenz emtricitabine tenofovir DF

Updated 5 times since 2017 Last updated: Dec 21, 2011 Started: Jan 31, 2006 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV Infections and Tuberculosis, this trial is completed. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 5 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

French National Agency for Research on AIDS and Viral Hepatitis

Data source: French National Agency for Research on AIDS and Viral Hepatitis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France